MGRC Healthcare, De Cell join hands to propel cell-gene therapy innovations

Malaysian Genomics Resource Centre Bhd (MGRC), a genomics and biopharmaceutical specialist, via their wholly owned subsidiary MGRC Healthcare Sdn Bhd has entered a strategic collaboration agreement (SCA) with De Cell Bhd to enhance the development and commercialisation of the pioneering Exogenetix programme, setting new standards in the field of cell-gene therapies.

Under this new strategic alliance, MGRC Healthcare will leverage its vast biopharmaceutical expertise to provide technical and production support, thereby optimising the operational efficiency and market deployment of the Exogenetix programme. Concurrently, De Cell will take on the role of the exclusive marketing partner, overseeing all promotional and trademark activities to amplify the programme’s market presence and success.

This collaboration underscores MGRC’s commitment to spearheading innovation and transforming healthcare outcomes through advanced biotechnologies. By combining MGRC Healthcare’s production capabilities with De Cell’s marketing acumen, this partnership is poised to significantly advance the reach and effectiveness of the Exogenetix programme.

Malaysian Genomics executive chairman Azri Azerai said the partnership not only aligns with their strategic vision to deliver cutting-edge healthcare solutions but also reinforces their dedication to pushing the boundaries of medical science.

Meanwhile, De Cell director Dr Lim Wooi Khai said the Exogenetix programme is a cornerstone of their strategy to bring innovative therapies to the market.

Through this partnership, he added they are set to accelerate the development and delivery of nextgeneration cell-gene therapies, ultimately improving patient outcomes.